Breaking News, Trials & Filings

BMS’ Belatacept BLA Accepted for Review

Bristol-Myers Squibb’s BLA for belatacept has been accepted for filing and review by the FDA.

Bristol-Myers Squibb’s BLA for belatacept has been accepted for filing and review by the FDA. The drug is currently in Phase III development for use in kidney transplantation.

“Belatacept has the potential to address significant unmet medical needs of transplant patients,” said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb. “We are pleased the FDA has accepted our submission and we look forward to continuing to work with the agency.”

Sign up today for Contracting & Outsourcing 2009!
contractpharma.com/2009conference

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters